Journal of Psychiatric Research

Major depressive disorder (MDD) is a severe psychiatric disorder that affects more than 350 million people worldwide, yet its biomolecular mechanisms are incompletely understood, and clinically applicable markers remain elusive. To shed new light on the underlying pathophysiology of MDD across multiple research disciplines, we first used a biochemical fingerprinting approach with human hair (the first 3 cm cut from the scalp) to identify changes in the total set of detectable metabolites and lipids (metabolipidomics) using quadrupole time-of-flight mass spectrometry (qToF-MS). In this study, we focused on endocannabinoid (ECB)-related lipid compounds and identified 7 candidate markers that differed between depressed and non-depressed female participants. Two phosphatidylinositols, namely PI 24:0 and PI 37:4, showed dose-dependent associations with the severity of depressive symptoms. Finally, to bridge hair findings with previously reported results in blood, we tested associations between changes in identified ECB-related compounds and parameters of mitochondrial respiratory activity in peripheral blood mononuclear cells. We found 17 significant associations, with the strongest effects for the lipids PI 24:0, MGDG-O 16:3, PG 12:0, and PI 37:4. Our approach not only identified novel associations between endocannabinoid (ECB)-related lipid dysregulation and impaired mitochondrial energy metabolism in MDD but also revealed ECB-related lipids as a possible surrogate marker of impaired bioenergetic metabolism in MDD, at least in immune cells. More research is needed to replicate these findings, ideally by testing reversibility in longitudinal intervention studies and by including both sexes in larger cohorts.

Background: Emotion dysregulation is a core feature of bipolar disorder (BD), yet its behavioral expression during depressive episodes, and potential differences between its types, BD-I and BD-II, remain unclear. This study used automated facial-expression analysis during naturalistic affective film viewing to examine subtype-specific and context-dependent emotional responding in bipolar depression. Methods: The sample included 135 participants: 69 healthy controls and 66 patients with BD (BD-I, 23; BD-II, 43). Participants viewed nine emotionally evocative film clips spanning negative, positive, neutral, and socially threatening contexts, while their facial expressions were continuously recorded and quantified using computer vision-based facial-expression analysis. Results: Patients with BD-I showed a distinct, context-dependent facial-expression profile, characterized by greater negative responses across multiple contexts than other groups. Specifically, they showed increased sadness during sad, reward, and amusing clips, and elevated anger during sad and neutral clips. In socially threatening contexts, BD-I participants showed a multivalent pattern of elevated anger, fear, and joy, suggesting poorly coordinated or context-incongruent affective expression. In contrast, BD-II participants did not differ significantly from healthy controls on any emotion, despite depressive symptom severity comparable to BD-I participants. Conclusions: These findings suggest that facial-expression patterns in bipolar depression differ across subtypes. BD-I may be characterized by heightened negative reactivity and altered context-appropriate modulation of emotional expression, whereas BD-II may not show comparable alterations in overt facial output. Automated facial-expression analysis during naturalistic stimulation may provide a useful behavioral marker for characterizing subtype-specific affective disturbance in bipolar depression and related psychopathology.

Accelerated 5x5 repetitive Transcranial Magnetic Stimulation (rTMS; five stimulation sessions per day for five days) is an effective treatment for Major Depressive Disorder (MDD), and has efficacy comparable to conventional once-daily rTMS. Considering the heterogeneity of symptoms in patients with MDD, it is critical to determine how accelerated 5x5 and conventional rTMS affect depression symptom domains. We compared symptom change over time in patients treated with either accelerated 5x5 rTMS (25 total sessions, n = 40) or conventional once-daily rTMS administered over six weeks (30 total sessions, n = 135). Accelerated 5x5 patients received either prolonged intermittent theta burst stimulation (piTBS) or personalized "resonant frequency" (RF) stimulation. Mixed-effects linear models were built to compare the two protocols, with the primary outcome variables being the Inventory of Depression Symptomology Self-Report (IDS), the Ruminative Response Scale (RRS), and the Profile of Mood States - Brief (POMS), yielding measures of 14 unique depression symptom domains. Both protocols led to similar improvements in all 14 depression symptom domains (all interaction term p-values > .05). Subsequent exploratory analyses demonstrated that accelerated 5x5 and conventional rTMS may differ in the time courses of their effects on anxiety, rumination, mood, depression, and vigor (p-values < .05, uncorrected). These results suggested that accelerated 5x5 rTMS has a similar efficacy in alleviating 14 depression symptom domains compared to conventional once-daily rTMS, and that either protocol may be appropriate for MDD patients with a variety of symptom profiles.

Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed blood-based biomarker and psychological changes following low-dose oral ketamine treatment for adults with MDD alone (n=14) and comorbid MDD+PTSD (n=21). Before treatment, the MDD clinical group presented with more severe depression, lower serotonin levels and higher kynurenine levels than the MDD+PTSD group. Post-treatment there were no detectable differences in the biological response between clinical groups, with combined analysis revealing common decreases in circulating brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF-A). Additionally, post-treatment, both clinical groups showed improvements in anxiety, stress, social functioning, suicidal ideation, and general well-being measures, as well as individual improvements in depression scores and PTSD symptoms in the MDD- and PTSD-containing groups, respectively. Collectively, this study presents additional evidence that low-dose oral ketamine treatment can be effective for MDD and MDD+PTSD, individually and comorbidly, and that both MDD and PTSD clinical groups responded in the same biological manner.

Accumulating evidence suggests alterations in neurocognitive, affective, interoceptive and autonomic processing in functional neurological disorder (FND), yet interventions targeting these processes remain underexplored. This study investigated the possible immediate and longer-term effects of a somatic yoga intervention on cognitive control, emotion regulation, state dissociation and affect, autonomic arousal, and interoceptive processing in FND. Twenty-three adults with FND completed six weeks of somatic yoga (N=12) or six weeks of a music-based relaxation control (N=11). At baseline, post-single session, and post-six weeks, participants completed laboratory measures of sustained attention, response inhibition, interoception, emotion regulation, and state dissociation and affect. Electrocardiography and galvanic skin conductance were recorded throughout. Linear mixed effects models assessed potential change on day one, immediately pre/post a single session, and from day 1 to the end of the six-week programme. After one session, stop signal reaction time, negative affect, and heartrate decreased in both groups ({Delta}=.69-.75). After one session and at six weeks, improved sustained attention, elevated positive affect, and reduced dissociation were seen in both groups, with a larger magnitude of change in yoga ({Delta}=.50-1.10). The yoga group exhibited fewer direction errors on the response inhibition task and shorter response times on the sustained attention task, with the opposite seen in the music group ({Delta}=.50-1.17). Both in the short- and longer-term, somatic yoga might lead to adaptive changes in attention and executive functioning, arousal, state affect and dissociation.

Background Multimorbidity is increasingly prevalent, and associated with worse clinical and psychosocial burdens. Interoception, the brain's ability to sense and interpret internal bodily signals, may contribute to multimorbidity, through its link with health behaviors, stress regulation, and mental health. This study examines whether self-reported interoceptive accuracy and attention is associated with multimorbidity, by identifying multimorbid subgroups and their interoceptive profiles. Methods Morbidity classes were identified through latent class analyses in two Dutch survey datasets, focusing on depression and alexithymia (DA-dataset; N = 671) and lifestyle factors (L-dataset; N = 1022). Linear regression analyses were used to assess interoceptive accuracy and attention (by the Interoceptive Accuracy Scale and Interoceptive Attention Scale respectively) among different subgroups. Results Multimorbid subgroups were characterized by older age, low socioeconomic position, and elevated physical, psychological, and behavioral problems. Multimorbid classes exhibited lower interoceptive accuracy (DA-dataset: B = -1.14, 95% CI = [-2.89, 0.62]; L-dataset: B = -2.36, 95% CI = [-3.83, -0.89]) and higher attention (DA-dataset: B = 3.62, 95% CI = [0.97, 6.27]; L-dataset: B = 1.07, 95% CI = [-1.42, 3.56]) compared to healthier classes. Conclusion Multimorbid populations demonstrated lower interoceptive accuracy and higher interoceptive attention. This highlights the psychosocial complexity of multimorbid populations which may impact their self-management and health behavior. These findings underscore the need to expand treatments to include psychosocial domains for multimorbid patients.

Suicidal behavior results from complex behavioral and biological changes. Previous cross-sectional studies indicate that proinflammatory immunobiological factors are often increased in close temporal proximity to a suicide attempt. Suicidal individuals may also exhibit a biological trait vulnerability to stress and inflammation, due to persistent epigenetic modifications. We enrolled 130 individuals with major depressive disorder (MDD), 83 with suicidal behavior at intake, and followed them for 12 months with up to eight clinical assessments. Quantification of plasma inflammatory markers and metabolites was performed by high-sensitivity electrochemiluminescence and Ultra High-Performance-Liquid-Mass Spectrometry (UPLC-MS), respectively. Epigenetic changes were identified using Illumina EPIC arrays. We identified 15 genes with altered DNA-methylation associated with suicidal behavior and attempts at baseline. Childhood trauma predicted lifetime suicide attempts and was associated with altered methylation of seven genes. Increased neutrophils and lower plasma serotonin at baseline predicted future suicide attempts over the following year (neutrophil estimate = 0.42, P = 0.016; serotonin OR = 0.58, 95% CI: 0.39-1.13). Utilizing biomarkers from baseline and epigenetic data from the genes with highest predictive values (STBD1 ,PRDM8, and TRIM15), we achieved an area under the curve (AUC) of 0.84 for suicide attempts over the year. Suicidal behavior in MDD was associated with specific epigenetic signatures. Several of the identified genes, such as MAD1L1, have been implicated in psychiatric disease, suicidal behavior and the immune response. These findings support the usefulness of epigenetic and immunometabolic blood markers for identifying suicidal individuals in clinical settings, potentially enhancing preventative efforts.

Background: In the age of TikTok, YouTube, and Netflix, video streaming (VS) is highly popular among adolescents. Yet, risky to addiction-like viewing patterns (i.e., problematic (P)VS) may adversely affect well-being. Prevalence estimates based on established criteria and etiological understanding of this phenomenon remain scarce. It is associated with de-pression, a major issue within the youth mental health crisis. However, causality remains unclear. This study investigated prevalence trends of adolescent PVS and its temporal rela-tionship with depression. Methods: Population-based data were drawn from four annual waves (2022-2025) of a rep-resentative online survey among 3,477 German adolescents (aged 10-17 years). Weighted annual PVS prevalence estimates were calculated based on standardized measures applying ICD-11 criteria of behavioural addictions distinguishing pathological from hazardous behav-ioural patterns. A cross-lagged panel analysis examined the reciprocal relationship between PVS and depression over four years. Results: Prevalence of pathological VS ranged between 2 to 4% across waves. Hazardous VS prevalence was 13-14% from 2022 to 2024, before increasing to 25% in 2025. Up to 81% of adolescents with pathological VS (21% with hazardous VS) showed clinically relevant symptoms of depression, versus 8-9% of non-affected adolescents. Depression significantly predicted PVS in two of three lags ({beta}W1-W2=0.233, {beta}W2-W3=0.155), but not vice versa. Conclusions: Prevalence rates and their divergent associations with depression support dis-tinguishing hazardous from pathological VS and underline the clinical relevance of PVS. Depression preceded PVS, pointing to the role of maladaptive coping. This has direct impli-cations for effective intervention measures. Future research should clarify the mechanisms underlying this relationship.

Background: Major depressive disorder (MDD) is a severe mental illness associated with severe clinical consequences and substantial societal burden. It's characterized by immune-inflammatory dysregulation and immune sensitization. Objective: To determine whether in vitro ketamine attenuates phytohemagglutinin (PHA)/lipopolysaccharide (LPS)-induced immune sensitization in patients with MDD and healthy controls (HCs). Methods: Whole blood from 18 patients with MDD and 18 HCs was stimulated with PHA/LPS and exposed to ketamine (0.3 M, 0.6 M, and 6 M) for 72 hours. Cytokines, chemokines, growth factors, and composite immune profiles, including M1/M2 macrophages, T helper (Th)1/2/17, the immune-inflammatory response system (IRS), and compensatory immunoregulatory system (CIRS), were synthesized and determined. Results: Under PHA and LPS stimulation in vitro, the MDD group exhibited markedly elevated immune profiles, including M1, M2, Th1, Th2, Th17, IRS, CIRS, chemokines, and growth factors, consistent with immune sensitization. Significant group-by-treatment interactions were observed for Th1-Th2, M2, growth factors, IL-12(p70), M1, and chemokines. Ketamine produced minimal changes in HCs but broader suppression in MDD, particularly at the highest concentration, without normalizing the sensitized immune phenotype. Among the immune markers with no notable group-by-treatment interactions, ketamine exerted diagnosis-independent effects, decreasing MIP-1{beta}, IL-1&{beta}, Th1, TNF-{beta} IRS, IFN-{gamma}, and IL-2 compared to the control condition. Conclusions: Ketamine exhibited two distinct immunoregulatory patterns: selective, disease-dependent attenuation of sensitized immune pathways and broader, diagnosis-independent suppression of the stimulated immune response, predominantly at higher concentrations. However, these effects were insufficient to normalize the immune-sensitized phenotype of MDD.

Cognitive deficits in depression often persist despite pharmacological and psychotherapeutic treatment. Existing cognitive retraining programs are typically time- and resource-intensive, and place limited emphasis on addressing subjectively perceived cognitive difficulties or generalization of gains. This proof-of-concept study aimed to adapt the Integrated Cognitive Control Training (ICCT) into a brief format for patients with depression and to generate preliminary evidence of feasibility and effectiveness. The intervention was adapted into a manualized five-session program through a literature review, expert surveys involving clinicians and individuals with lived experience of depression, and a trial run. The study followed a single-group, open-label pre-post design (N = 16). Significant improvements were observed in cognitive flexibility (Color Trails Test-2: t = 3.52, p = 0.003, d = 0.88), depression severity (Montgomery-[A]sberg Depression Rating Scale: t = 6.66, p < 0.001, d = 1.67), and subjective cognition (Perceived Deficits Questionnaire: t = 5.06, p < 0.001, d = 1.3). The intervention demonstrated high acceptability and demand. These findings suggest that the Brief ICCT is a feasible and potentially effective approach for addressing cognitive deficits, with improvements extending to depressive symptom severity and socio-occupational functioning. These proof-of-concept findings justify further evaluation of Brief ICCT in adequately powered randomized controlled trials.

Background Depressive disorders are among the most common mental disorders, often emerging in adolescence. Despite advances in biological psychiatry, research on early psychopathology remains scarce. Given the heterogeneity and comorbidity of depressive disorders, identifying biologically informed phenotypes could enhance diagnostic accuracy and personalized treatment approaches. Methods This study utilized baseline and 6-month follow-up plasma samples (n=47) and clinical data (n=103) of adolescent outpatients with depression (DD, aged 14-19) from the Finnish SMART study and healthy control samples (HC, n=53, aged 15-16) from the Finnish PANIC study. Fasting plasma samples were analyzed using untargeted liquid chromatography-tandem mass spectrometry for proteomics. Data analyses included dimensionality reduction, regression models, correlation analysis, functional enrichment, and factor analysis of mixed data with k-means clustering, including 72 symptom-related items, lifestyle, and socioeconomic scales. Results Among 756 proteins detected in DD and HC, 308 proteins showed notable, significant (adjusted p<0.01 and Log2FC [&ge;]|1|) alterations in depression. These proteins were enriched in stress-response pathways, including complement and coagulation cascades, energy metabolism, the proteasome complex, and growth factor signaling. Additionally, extracellular matrix proteins were altered. Clinical phenotypes were mostly distinguished by symptom severity, bullying victimization and other trauma-related experiences, social relationships, and medication. Improvement in mood over the 6-month follow-up was associated with shifts in proteins involved in extracellular matrix, cytoplasmic vesicles, and complement and coagulation cascades. Conclusions Together, adolescent depression displays shared plasma proteomic signatures across its clinical phenotypes, and systemic immune dysfunction, oxidative stress, and extracellular matrix are potential targets for biologically informed interventions in depression.

Circadian biology has long been implicated in mood and depressive disorders. While longer, infradian rhythms are increasingly recognised across diverse physiological processes, their relevance to mood remains poorly understood. Using long-term wearable heart rate data, this study mapped depressive symptom severity onto person-specific multiday physiological phase. Individual-specific cycles were estimated from 413 young adult participants (Notre Dame NetHealth project) alongside up to four repeated Beck Depression Inventory (BDI) assessments (955 observations). Individual's dominant infradian rhythm (2-60 days) was estimated from heart rate using wavelet analysis, and BDI scores were indexed according to whether surveys occurred during the cycle peak or trough. Mixed-effects linear modelling examined the relationship of cycle phase with mood symptoms, and whether this relationship differed by exercise level. In those with significant cycles (360 participants, 864 observations), depressive symptom severity varied across multiday physiological phase as a function of exercise level: Cycle Phase X Exercise Group interaction, F(1,712.21)=5.13, p=0.024. BDI scores were higher at the peak than trough in the Low-exercise group, {Delta} = 1.69, 95% CI [0.11, 3.28], p=0.037, with no peak-trough difference in the Higher-exercise group. Higher daily heart rate, lower exercise, female sex, and winter season were associated with higher BDI scores. Notably, this study introduces a "when" dimension to depressive symptom variation and provides the groundwork for clinical studies testing whether wearable-derived cycles can characterise temporal patterns of symptom vulnerability and support personalised tracking of mood dynamics.

Background: Metabolomic studies of depression have yielded heterogeneous findings, potentially because metabolic correlates differ across symptoms and metabolic states. We examined symptom-specific metabolomic associations and whether body mass index (BMI) modifies these relationships. Methods: We analyzed 83,717 Estonian Biobank participants (70.6% female) with 249 Nightingale metabolite measures and 14 lifetime depressive symptoms. Logistic regression models progressively adjusted for sociodemographic, lifestyle, medication, and BMI factors. BMI-related attenuation and metabolite x BMI interactions were evaluated, followed by self-organizing map analyses of broader metabolic context. Results: Before BMI adjustment, 660 metabolite-symptom associations were Bonferroni-significant; 136 were significant after BMI adjustment, including 105 retained associations. Weight-related associations showed the strongest BMI dependence: none of 199 weight-gain associations and 2 of 115 weight-loss associations were retained. Among 691 preselected metabolite-symptom pairs, 211 (30.5%) showed significant metabolite x BMI interactions after false discovery rate correction. Six systemic metabolic profiles were identified, but only 3 of 211 BMI-sensitive pairs showed additional profile-dependent heterogeneity. Conclusions: Circulating metabolic correlates of depressive symptoms are heterogeneous and strongly dependent on symptom phenotype and BMI-related metabolic context. These findings suggest that metabolic biomarkers in depression should be interpreted in relation to both symptom presentation and metabolic state rather than as uniform correlates of the disorder.

Background: Substance use is common among individuals with depression. Transcranial magnetic stimulation (TMS) is an effective treatment for depression, but current clinical guidelines have discouraged TMS treatment for individuals with depression and co-occurring substance use given concerns for limited efficacy. However, limited data exists on whether substance use affects response to TMS. Methods: Using electronic health record data from patients who received a standard course of TMS for major depressive disorder at an academic medical center, we investigated associations between substance use frequency and response to TMS, defined as change in Patient Health Questionnaire-9 (PHQ-9) scores. Substance use frequency was extracted for alcohol, cannabis, nicotine, stimulants, benzodiazepines, opioids, inhalants, psychedelics, and other drugs. We performed ANCOVA and multiple regression analyses to predict change in PHQ-9 score based on substance use frequency, controlling for pre-TMS PHQ-9 score, age, sex, and number of TMS sessions received. Results: We extracted data from 219 TMS courses. Alcohol was the substance used most commonly (34.2%), followed by prescription benzodiazepines (28.3%), and prescription stimulants (21.0%). Across all substance categories, substance use was not associated with change in PHQ-9 score (all p > 0.05, Cohens d=0.00 to 0.30). In multiple regression models to compare individual levels of substance use frequency (e.g., daily use vs. no use), level of substance use was not associated with change in PHQ-9 score (all p > 0.05). The range of plausible effects of substance use frequency on PHQ-9 change was generally below the minimal clinically important difference for PHQ-9, suggesting substance use was unlikely to have a meaningful clinical effect on antidepressant response to TMS. Conclusions: Low to moderate substance use does not have a clinically significant effect on antidepressant response to TMS. Low-level substance use should not exclude individuals with depression from receiving TMS.

Background: Major depressive disorder is a severe, recurrent and disabling condition. Although diagnosis and clinical monitoring are based on medical interviews and validated rating scales, speech and discourse analysis may provide complementary digital biomarkers reflecting depressive severity and clinical evolution. However, current evidence remains limited by methodological heterogeneity, predominantly cross-sectional designs, limited longitudinal data and underrepresentation of non-English-speaking clinical populations. Objective: The aim of the VOICE-DEP study is to develop and formalize a standardized, reproducible and clinically grounded protocol for the multimodal analysis of voice and discourse during medical interviews as a tool to support the diagnosis of depressive disorder and to assess whether speech-derived biomarkers change over time in parallel with clinical severity measures. Methods: VOICE-DEP is an observational, prospective, longitudinal pilot study of patients with major depressive disorder with a healthy control group, conducted in a hospital-based clinical setting in Spain. The study will include 25 adult patients with moderate or severe unipolar depression, with or without psychotic symptoms, and 50 healthy controls without a personal history of psychiatric disorders. Patients will be assessed at five time points: baseline (V0) and four monthly follow-up visits at 30, 60, 90 and 120 days. Healthy controls will be assessed once at baseline. The planned dataset comprises 175 voice recordings: 125 from patients and 50 from controls. At each assessment, the Montgomery-Asberg Depression Rating Scale related part of the medical interview, lasting approximately 10-30 minutes and including an initial free-speech segment, will be recorded using a standardized audio protocol. Acoustic, paralinguistic and linguistic features will be extracted and analyzed in relation to clinician-rated severity measures and self-reported symptoms. Ethics: This protocol has been reviewed and approved by the local Research Ethics Committee, which complies with the international standards of GCP CPMP/ICH/135/95 (Comunidad Foral de Navarra Research Ethics Committee; reference code: 2026.110). Written informed consent will be obtained from all participants before any study procedure. Voice recordings and clinical data will be pseudonymized, stored securely and processed in accordance with applicable Spanish and European data protection regulations. Expected outcomes: This protocol is expected to generate a clinically grounded Spanish-language longitudinal speech corpus and a transparent analytical framework for evaluating voice- and discourse-derived biomarkers as complementary tools for depression assessment and monitoring

Ayahuasca use has expanded beyond its traditional Amazonian contexts, yet prospective longitudinal data examining depressive symptoms following naturalistic use in the United States remain limited. We conducted an interim analysis of an ongoing prospective observational cohort of adults participating in naturalistic ayahuasca use in Las Vegas, Nevada. Depressive symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9), with higher scores indicating greater depressive symptom severity, at baseline and approximately 48 hours, 30 days, 60 days, and 90 days following exposure. At interim analysis, PHQ-9 data were available for 87 participants at baseline, 61 at 48 hours, 41 at 30 days, 33 at 60 days, and 26 at 90 days. Mean PHQ-9 scores decreased from 8.06 (SD 5.96) at baseline to 4.39 at 48 hours, 3.76 at 30 days, 3.97 at 60 days, and 3.65 at 90 days. Among participants with matched baseline and follow-up assessments, mean changes were -3.58 points at 48 hours, -4.47 at 30 days, -4.48 at 60 days, and -4.76 at 90 days. In a mixed-effects model accounting for repeated observations, PHQ-9 scores remained significantly lower than baseline at 48 hours ({beta}=-3.70; 95% CI -5.09 to -2.31), 30 days ({beta}=-4.34; 95% CI -6.01 to -2.67), 60 days ({beta}=-3.97; 95% CI -5.77 to -2.18), and 90 days ({beta}=-4.25; 95% CI -6.18 to -2.33; all p<0.001). Among participants with baseline PHQ-9 scores [&ge;]5 and matched follow-up data, 69.2% demonstrated a reduction of at least 5 points at 90 days. These interim findings provide preliminary evidence of a sustained longitudinal association between naturalistic ayahuasca exposure and lower depressive symptom scores through 90 days in a U.S.-based cohort. The observational design, self-selection, incomplete follow-up, and absence of a control group preclude causal inference. Continued longitudinal follow-up is needed to determine the durability of this association.

Objective: Observational studies have provided evidence for positive associations between inflammatory dietary patterns (IDP) and mental health, which might be mediated by immune activation. However, a causal relationship has not yet been established. Here we aim to investigate the causal nature of associations between IDP and mental health traits (depressed affect, mood swings, neuroticism, feed-up feelings, worry, irritability) using Mendelian Randomization (MR) analyses. Method: In the UK Biobank dataset, IDP was identified by conducting a partial least squares regression (PLSR) on the items of the food frequency questionnaire along with three inflammatory biomarkers as response variables: C-reactive protein, platelets, and white blood cell (WBC) counts. An individual-level genome-wide association study (GWAS) of IDP was performed within an unrelated European subsample from the UK Biobank (n=320,137) and summary-level GWAS data for mental health traits were utilized for bi-directional two-step MR to test the association between genetically predicted IDP and mental health traits. Result: The first PLSR component was retained for subsequent analysis, with a higher IDP score indicating a more frequent consumption of processed meat, beef, pork, lamb/mutton, and poultry. Genome-wide association analysis identified 101 independent genomic loci. MR analyses indicated a uni-directional positive relationship from IDP to neuroticism and a positive bi-directional relationships between IDP and depressed affect, mood swings, fed-up feelings, and irritability. The mediation effect of total white blood cell count on neuroticism score was also significant (adjusted P<0.05). Conclusion: Our findings identified genetic loci and functional properties of IDP and provided evidence for causal pathways with depressed affect, mood swings, irritability, and fed-up feelings. Implementing dietary advice and interventions should become part of a public mental health approach. Keywords: Inflammatory dietary pattern; Partial least squares regression; Genome-wide association study; Mendelian Randomization; Mental health.

Emerging evidence suggests that adults with a history of early life adversity (ELA), while more susceptible to psychopathology, may also be particularly sensitive to the benefits of contemplative practices. In the present study, we examined whether ELA was associated with greater mental health benefits following a contemplative-based social resilience training program, administered as a university elective course across all ten campuses of the University of California (n = 321; median age = 21 years; 74% female). While significant improvements in mental health were observed for all participants, those with higher ELA exhibited greater reductions in mental distress (3.5-fold larger, p = .007) and greater increases in well-being (2.5-fold larger, p = .010) relative to those with lower ELA. Replication in future studies and further research on the mechanisms underlying this enhanced benefit may improve our understanding of how adults with a history of ELA recover and may ultimately thrive.

Introduction: Cognitive impairment and disturbed rest-activity patterns often persist between episodes of major depressive disorder (MDD) and bipolar disorder (BD). Whether these deficits are disorder-specific or transdiagnostic remains unclear, as does the existence of a link between rest-activity phenotypes and cognitive performance. Methods: Using the All of Us Research Program, we derived normative deviation scores across four cognitive domains (sustained attention, inhibitory control, reward-based impulsivity, social cognition) from non-clinical controls (NCC), then compared deviations in MDD and BD. MDD was adequately powered to regress deviation scores on four 90-day Fitbit-derived phenotypes (step count, sleep duration, wakefulness after sleep onset, sleep timing variability); the same analysis was run on NCC as a sensitivity check. Results: Samples were substantially larger than prior works (MDD 5,087-6,536; BD 545-739; NCC 40,589-51,491). Relative to NCC, MDD and BD exhibited worse sustained attention (Delta Glass = -0.081 vs. -0.187) and higher impulsivity (Delta Glass = 0.092 vs. 0.240), with deficits more pronounced in BD. No wearable phenotype was significantly associated with cognitive performance in MDD (R2< 0.01); NCC associations, though significant, were of negligible magnitude (R2 <= 1.2%). Discussion: Inter-episode cognitive impairment was domain-selective rather than global, with a gradient BD > MDD. Despite adequate power, wearable rest-activity phenotypes were not associated with cognition in MDD. Whether this extends to BD, where deficits were largest, could not be tested due to limited power. Community-dwelling samples likely underestimate impairment relative to clinical cohorts.

Background: The October 7, 2023 attack in southern Israel was one of the deadliest terror attacks in modern history, with 1,182 fatalities, more than 4,000 wounded individuals, and 251 hostages. The Nova music festival, an all-night outdoor rave near the Gaza border, suffered the highest number of civilian casualties, with more than 370 festival attendees killed. Survivors were exposed to prolonged life-threatening trauma with similar characteristics and within a narrow time window. Many survivors also reported being under the acute influence of psychoactive substances during the attack and the following hours. This tragic combination of civilian mass trauma and naturalistic pharmacological exposure created a rare opportunity to study trauma processing prospectively. Objective: This paper describes the rationale, design, and methodology of the Nova Protocol, a multimodal longitudinal observational study of survivors of the October 7, 2023 Nova festival attack and a sociocultural comparison group. Methods: The protocol spans from the first weeks to approximately 24 months post-trauma and includes three major assessment time points. It integrates repeated online clinical assessments, prolonged wearable-sensor monitoring, ecological assessments, saliva-based endocrine and inflammatory markers, structural and functional MRI, cardiac interoception paradigms, online and in-scanner reinforcement-learning tasks, and semi-structured qualitative interviews. Primary outcomes are PTSD symptom severity (PCL-5) and general psychological distress (K6), supplemented by a rich battery of secondary measures. Conclusion: The Nova Protocol provides an unusually rich longitudinal framework for characterizing psychological, behavioral, physiological, inflammatory, neural, interoceptive, and subjective mechanisms that shape clinical trajectories after civilian mass trauma. Because psychoactive substance exposure was naturalistic and self-selected, findings will be interpreted as mechanistic and prognostic associations rather than causal effects. The protocol is expected to inform early risk detection and scalable post-disaster monitoring and intervention strategies, as well as unique insights into how psychoactive substances impact trauma processing.